Acrivon Therapeutics, Inc.ACRV

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · acrivon.com

Acrivon Therapeutics is a clinical stage biopharmaceutical company discovering and developing precision medicines using its proprietary Generative Phosphoproteomics AP3 platform, which interprets drug-regulated pathway activity inside intact cells to guide rational drug design. Its lead program, ACR-368 (prexasertib), targets CHK1/CHK2 in a potentially registrational Phase 2 trial for endometrial cancer, alongside pipeline programs including ACR-2316 (WEE1/PKMYT1 inhibitor).

Key ratios

ROA

-32.2%2025

2024 -33.3%2023 -26.3%

ROE

-53.9%2025

2024 -54.1%2023 -41.4%

Recent news

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer 2026-08-31 · GlobeNewswire

Track ACRV in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer